Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
detroit blog main
detroit top stories
indiana blog main
indiana top stories
investing
7
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
pfizer
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
7
×
san francisco top stories
seattle blog main
seattle top stories
startups
7
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
fda
alzheimer's disease
cancer
eli lilly
astrazeneca
merck
nonalcoholic steatohepatitis
regeneron pharmaceuticals
What
bio
7
×
roundup
7
×
develop
drug
alzheimer’s
amid
bombast
cancer
caught
companies
coronavirus
debate
discussion
efforts
growing
meso’s
miss
pandemic
pfizer’s
pharmaceutical
presidential
prices
promise
response
tuesday’s
typically
vaccine
viewers
alliance
annual
approved
assessed
attention
bails
biotech
brand
bridgebio
bristol
buy
calls
Language
unset
Current search:
investing
×
bio
×
" san francisco blog main "
×
startups
×
roundup
×
pfizer
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More